Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Importantly, the top predicted drug candidates are associated with distinct MOAs, including HMGCR inhibitors, i.e., statins and vitamin D receptor agonists, frequently across microarray and RNAseq TB datasets (Table 2 and Section 3.5).

Source: Predicted candidate HDTs with literature evidence against TB. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

These human gene expression datasets spanned a variety of biological and experimental conditions, such as time points, cell lines, primary tissues, and experimental platforms, providing a practical foundation of data heterogeneity for our analysis.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Integrative transcriptome-based drug repurposing in tuberculosis

Study design awaiting verification · bioRxiv · 2025

Original publication title

Integrative transcriptome-based drug repurposing in tuberculosis

Kewalin Samart; Landon Buskirk; Amy Tonielli; Arjun Krishnan; Janani Ravi

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Tuberculosis (TB) remains the second leading cause of infectious disease mortality worldwide, killing over one million people annually. Rising antibiotic resistance has created an urgent need for host-directed therapeutics (HDTs): preferably by repurposing existing approved drugs: that modulate host immune responses rather than directly targeting the pathogen. Repurposed therapeutics have been successfully identified for cancer and COVID-19 by finding drugs that reverse disease gene expression patterns (an approach called ‘connectivity scoring’), but this approach remains largely unexplored for bacterial infections like TB.

The application of transcriptome-based methods to TB faces significant challenges, including dataset heterogeneity across transcriptomics platforms and biological conditions, uncertainty about optimal scoring methods, and lack of systematic approaches to identify robust disease signatures. Here, we developed an integrative computational workflow combining multiple connectivity scoring methods with consensus disease signature construction and used it to systematically identify FDA-approved drugs as promising TB host-directed therapeutics. Our framework integrates six complementary connectivity methods and constructs weighted consensus signatures from 21 TB gene expression datasets spanning microarray and RNA-seq platforms, diverse cell types, and infection conditions.

Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways. Network analysis of disease-drug interactions identified 10 key bridging genes (including MYD88, RELA, and CXCR2) that represent potential novel druggable targets for TB host-directed therapy.

This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis.

Authors’ abstract

Tuberculosis (TB) remains the second leading cause of infectious disease mortality worldwide, killing over one million people annually. Rising antibiotic resistance has created an urgent need for host-directed therapeutics (HDTs): preferably by repurposing existing approved drugs: that modulate host immune responses rather than directly targeting the pathogen. Repurposed therapeutics have been successfully identified for cancer and COVID-19 by finding drugs that reverse disease gene expression patterns (an approach called ‘connectivity scoring’), but this approach remains largely unexplored for bacterial infections like TB.

The application of transcriptome-based methods to TB faces significant challenges, including dataset heterogeneity across transcriptomics platforms and biological conditions, uncertainty about optimal scoring methods, and lack of systematic approaches to identify robust disease signatures. Here, we developed an integrative computational workflow combining multiple connectivity scoring methods with consensus disease signature construction and used it to systematically identify FDA-approved drugs as promising TB host-directed therapeutics. Our framework integrates six complementary connectivity methods and constructs weighted consensus signatures from 21 TB gene expression datasets spanning microarray and RNA-seq platforms, diverse cell types, and infection conditions.

Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways. Network analysis of disease-drug interactions identified 10 key bridging genes (including MYD88, RELA, and CXCR2) that represent potential novel druggable targets for TB host-directed therapy.

This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis.

Publication and source details

Original title: Integrative transcriptome-based drug repurposing in tuberculosis

Kewalin Samart; Landon Buskirk; Amy Tonielli; Arjun Krishnan; Janani Ravi

bioRxiv · 2025

Author Contributions

KS obtained the microarray data and constructed the associated disease signatures, designed and built the workflow, performed disease-drug comparison and other downstream analyses, acquired results, and drafted and revised the manuscript. LB conducted the baseline comparison analysis. AT obtained the RNAseq data and constructed RNAseq disease signatures. JR and AK conceived the study, provided guidance throughout the project, and contributed to the design of the workflow, interpretation of the results, and revision of the manuscript.

* Corresponding authors: arjun.krishnan@cuanschutz.edu, janani.ravi@cuanschutz.edu
https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.This work was supported by the NIH NIAID R21 AI169301, Mechanism-guided drug repurposing for host-directed therapy of infectious diseases using interpretable, integrative ML, awarded to AK and JR. Additional funding was provided by the Colorado Translational Research Scholars Program to JR, and start-up funds awarded to AK and JR.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:49:21.868533+00:00

DOI: 10.1101/2025.06.02.657296 · PMC12157595